Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8

Digestive Diseases and Sciences

Volumn 56, Issue 5, 2011, Pages 1524-1534

  Shanab, Ahmed Abu ^a   Scully, Paul ^a   Crosbie, Orla ^b   Buckley, Martin ^c   O'Mahony, Liam ^d   Shanahan, Fergus ^a   Gazareen, Sanaa ^e   Murphy, Eileen ^a   Quigley, Eamonn M M ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

^c MERCY UNIVERSITY HOSPITAL   (Ireland)

^d SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^e MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Interleukin 8; Lipopolysaccharide; Microbiota; Nonalcoholic steatohepatitis; Small intestinal bacterial overgrowth; Toll like receptor 4

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL OVERGROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BREATH TEST; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMALL INTESTINAL BACTERIAL OVERGROWTH;

ACUTE-PHASE PROTEINS; ADULT; BREATH TESTS; CARRIER PROTEINS; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-8; INTESTINE, SMALL; LACTULOSE; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; TOLL-LIKE RECEPTOR 4;

EID: 79955597671     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1447-3     Document Type: Article

References (105)

1. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419. (Pubitemid 29258890)
2. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321. (Pubitemid 40770284)
3. Maeda T, Hashimoto K, Kihara Y, et al. Surgically resected hepatocellular carcinomas in patients with non-alcoholic steatohepatitis. Hepatogastroenterology. 2008;55:1404-1406.
4. Day CP, James O. Steatohepatitis: A tale of two "hits"? Gastroenterology. 1998;114:842-845.
5. Day CP. Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going? Gut. 2002;50:585-588.
6. Namikawa C, Zhang H, Toi M. Non-alcoholic steatohepatitis: Pathology and pathogenesis. Nippon Rinsho. 2006;64:1107-1113.
7. Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology. 1989;36:349-351. (Pubitemid 19284541)
8. Zhao LF, Jia JM, Han DW. The role of enterogenous endotoxemia in the pathogenesis of non-alcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi. 2004;12:632.
9. Fu JF, Fang YL, Liang L, et al. A rabbit model of pediatric nonalcoholic steatohepatitis: The role of adiponectin. World J Gastroenterol. 2009;15:912-918.
10. Soza A, Riquelme A, Gonzalez R, et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2005;50:1136-1140. (Pubitemid 40864023)
11. Fan JG, Xu ZJ, Wang GL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol. 2005;11:5053-5056.
12. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206-211. (Pubitemid 32141844)
13. Riordan SM, McIver CJ, Williams R. Liver damage in human small intestinal bacterial overgrowth. Am J Gastroenterol. 1998;93:234-237. (Pubitemid 29063975)
14. Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol. 2008;14:313-317. (Pubitemid 351314317)
15. Cuoco L, Montalto M, Jorizzo RA, et al. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology. 2002;49:1582-1586. (Pubitemid 35277332)
16. Basilisco G, Camboni G, Bozzani A, et al. Orocecal transit delay in obese patients. Dig Dis Sci. 1989;34:509-512. (Pubitemid 19121986)
17. Sabate JM, Jouet P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obes Surg. 2008;18:371-377.
18. Pilotto A, Franceschi M, Del Favero G, et al. The effect of aging on oro-cecal transit time in normal subjects and patients with gallstone disease. Aging (Milano). 1995;7:234-237.
19. Elphick DA, Chew TS, Higham SE, et al. Small bowel bacterial overgrowth in symptomatic older people: Can it be diagnosed earlier? Gerontology. 2005;51:396-401.
20. Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci. 1997;42:738-742. (Pubitemid 27196023)
21. Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology. 1993;17:828-832. (Pubitemid 23150092)
22. Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98:1362-1370. (Pubitemid 36741535)
23. Chang CS, Chen GH, Lien HC, et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28:1187-1190.
24. Pardo A, Bartoli R, Lorenzo-Zuniga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology. 2000;31:858-863. (Pubitemid 30169931)
25. Gao Y, Song LX, Jiang MN, et al. Effects of traditional Chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation. 2008;31:121-132.
26. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006;103:12511-12516. (Pubitemid 44267289)
27. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772. (Pubitemid 47025442)
28. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94:2557-2562. (Pubitemid 27136914)
29. Drewe J, Beglinger C, Fricker G. Effect of ischemia on intestinal permeability of lipopolysaccharides. Eur J Clin Invest. 2001;31:138-144. (Pubitemid 32199907)
30. Neal MD, Leaphart C, Levy R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol. 2006;176:3070-3079.
31. Moore FA, Moore EE, Poggetti R, et al. Gut bacterial translocation via the portal vein: A clinical perspective with major torso trauma. J Trauma. 1991;31:629-636.
32. Tomita M, Ohkubo R, Hayashi M. Lipopolysaccharide transport system across colonic epithelial cells in normal and infective rat. Drug Metab Pharmacokinet. 2004;19:33-40.
33. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431-1433.
34. Vreugdenhil AC, Rousseau CH, Hartung T, et al. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol. 2003;170:1399-1405. (Pubitemid 36139507)
35. Wu RQ, Xu YX, Song XH, et al. Adhesion molecule and pro-inflammatory cytokine gene expression in hepatic sinusoidal endothelial cells following cecal ligation and puncture. World J Gastroenterol. 2001;7:128-130. (Pubitemid 32170913)
36. Gutsmann T, Muller M, Carroll SF, et al. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun. 2001;69:6942-6950. (Pubitemid 32995454)
37. Heumann D, Adachi Y, Le Roy D, et al. Role of plasma, lipopolysaccharide-binding protein, and CD14 in response of mouse peritoneal exudate macrophages to endotoxin. Infect Immun. 2001;69:378-385. (Pubitemid 32038335)
38. Tobias PS, Soldau K, Gegner JA, et al. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem. 1995;270:10482-10488.
39. Romics L Jr, Mandrekar P, Kodys K, Velayudham A, Drechsler Y, Dolganiuc A, Szabo G. Increased lipopolysaccharide sensitivity in alcoholic fatty livers is independent of leptin deficiency and toll-like receptor 4 (TLR4) or TLR2 mRNA expression. Alcohol Clin Exp Res. 2005;9:1018-1026. (Pubitemid 40934206)
40. Medvedev AE, Vogel SN. Overexpression of CD14, TLR4, and MD-2 in HEK 293T cells does not prevent induction of in vitro endotoxin tolerance. J Endotoxin Res. 2003;9:60-64. (Pubitemid 36322487)
41. Nagai Y, Akashi S, Nagafuku M, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002;3:667-672. (Pubitemid 34752476)
42. Tazi KA, Quioc JJ, Saada V, et al. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: Possible role of Akt and IRAK-M. J Hepatol. 2006;45:280-289. (Pubitemid 44026567)
43. Paik YH, Schwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37:1043-1055. (Pubitemid 36538681)
44. Thurman RG, Bradford BU, Knecht KT, et al. Endotoxin, Kupffer cells and alcoholic liver injury. In: Blum HE, Bode Ch, Bode JCh, Sartor RB (ed) Gut and the liver. Falk Symposium 100, Dordrecht, The Netherlands. Kluwer Academic Publishers Group, 1997:222-240.
45. Bode Ch, Schafer C, Bode JCh. The role of gut derived bacterial toxins (endotoxin) for the development of alcoholic liver disease in man. In: Blum HE, Bode Ch, Bode JCh, Sartor RB (ed) Gut and the liver. Falk Symposium 100, Dordrecht, The Netherlands. Kluwer Academic Publishers Group, 1997:281-298.
46. McClain CJ, Song Z, Barve SS, et al. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2004;287:G497-G502. (Pubitemid 39096613)
47. Copaci I, Micu L, Voiculescu M. The role of cytokines in nonalcoholic steatohepatitis. A review. J Gastrointest Liver Dis. 2006;15:363-373. (Pubitemid 46119279)
48. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46-54.
49. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413-419. (Pubitemid 36919862)
50. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34: 1158-1163. (Pubitemid 33096588)
51. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185-194. (Pubitemid 38868937)
52. Jung BD, Kimura K, Kitamura H, et al. Norepinephrine stimulates interleukin-6 mRNA expression in primary cultured rat hepatocytes. J Biochem. 2000;127:205-209. (Pubitemid 30136902)
53. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467-1476.
54. West DA, James NH, Cosulich SC, et al. Role for tumor necrosis factor a receptor 1 and interleukin-1 receptor in the suppression of mouse hepatocyte apoptosis by the peroxisome proliferator nafenopin. Hepatology. 1999;30:1417-1424.
55. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152. (Pubitemid 39071617)
56. Nonalcoholic steatohepatitis clinical research network. Hepatology. 2003;37:244.
57. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95:982-988.
58. Corazza GR, Strocchi A, Gasbarrini G. Fasting breath hydrogen in celiac disease. Gastroenterology. 1987;93:53-58. (Pubitemid 17084093)
59. Perman JA, Modler S, Barr RG, et al. Fasting breath hydrogen concentration: Normal values and clinical application. Gastroenterology. 1984;87:1358-1363. (Pubitemid 15201436)
60. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333. (Pubitemid 43381675)
61. Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802-808. (Pubitemid 46854194)
62. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-419. (Pubitemid 36232393)
63. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: Comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566-1570. (Pubitemid 41032365)
64. Bratten JR, Spanier J, Jones MP. Lactulose hydrogen breath testing (LHBT) in patients with IBS and controls: Differences in methane (CH4) but not hydrogen (H2). Am J Gastroenterol. 2006;101:S479.
65. Simon D, Borelli S, Braathen LR, Simon HU. Peripheral blood mononuclear cells from IgE- and non-IgE-associated allergic atopic eczema/dermatitis syndrome (AEDS) demonstrate increased capacity of generating interleukin-13 but differ in their potential of synthesizing interferon-gamma. Allergy. 2002;57:431-435. (Pubitemid 34442157)
66. Bihl T, Vassina E, Boettger MK, et al. The T348M mutated form of cryopyrin is associated with defective lipopolysaccharide-induced interleukin 10 production in CINCA syndrome. Ann Rheum Dis. 2005;64:1380-1381. (Pubitemid 41206268)
67. de Oliveira CP, Stefano JT, de Siqueira ER, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res. 2008;38:159-165.
68. Gisbert JP, Gonzalez-Lama Y. Breath tests in the diagnosis of gastrointestinal diseases. Gastroenterol Hepatol. 2005;28:407-416. (Pubitemid 41345546)
69. Kristensen M, Hoeck HC. Abnormal flora in the small intestine. Diagnostic evaluation of the H2 breath test. Ugeskr Laeger. 1994;156:7530-7533.
70. Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: An evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol. 2002;97:1113-1126. (Pubitemid 34478108)
71. Bauer TM, Schwacha H, Steinbruckner B, et al. Diagnosis of small intestinal bacterial overgrowth in patients with cirrhosis of the liver: Poor performance of the glucose breath hydrogen test. J Hepatol. 2000;33:382-386. (Pubitemid 30663375)
72. Farrell G. Is bacterial ash the flash that ignites NASH? Gut. 2001;48:148-149.
73. Sajjad A, Mottershead M, Syn WK, et al. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;22:291-299. (Pubitemid 41207458)
74. Reilly JA Jr, Quigley EM, Forst CF, et al. Small intestinal transit in the portal hypertensive rat. Gastroenterology. 1991;100:670-674.
75. Casafont Morencos F, de las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1996;41:552-556.
76. Prytz H, Holst-Christensen J, Korner B, et al. Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis. Scand J Gastroenterol. 1976;11:857-863. (Pubitemid 8012231)
77. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 1988;8:232-236.
78. Hurley JC, Tosolini FA, Louis WJ. Quantitative limulus lysate assay for endotoxin and the effect of plasma. J Clin Pathol. 1991;44:849-854.
79. Jin X, Yu CH, Lv GC, et al. Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats. World J Gastroenterol. 2007;13:1732-1736. (Pubitemid 46711347)
80. Tarao K, So K, Moroi T, et al. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: Its clinical significance. Gastroenterology. 1977;73:539-542. (Pubitemid 8170947)
81. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374-1380.
82. Kopp E, Medzhitov R. Recognition of microbial infection by toll-like receptors. Curr Opin Immunol. 2003;15:396-401. (Pubitemid 36930075)
83. Igolnikov AC, Green RM. C3H/HEJ mice with mutations of the toll-like receptor 4 (TLR-4) are resistant to the methioninecholine deficient (MCD) diet induced non-alcoholic steatohepatitis (NASH). Hepatology. 2003;36:A404.
84. Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47:571-579. (Pubitemid 47331747)
85. Stadlbauer V, Mookerjee RP, Hodges S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol. 2008;48:945-951.
86. Szabo G, Velayudham A, Romics L Jr, et al. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: The role of toll-like receptors 2 and 4. Alcohol Clin Exp Res. 2005;29(11 Suppl):140S-145S.
87. Tuncer I, Özbek H, Topal H, Uygan I. The serum levels of IL-1B, Il-6, IL-8 and TNF alpha in non alcoholic fatty liver disease. Turk J Med Sci. 2003;33:381-386.
88. Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology. 2005;52:1549-1553.
89. Torer N, Ozenirler S, Yucel A, et al. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand J Gastroenterol. 2007;42:1095-1101. (Pubitemid 47301137)
90. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412-421.
91. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology. 1999;117:942-952. (Pubitemid 29468238)
92. McClain C, Hill D, Schmidt J, et al. Cytokines and alcoholic liver disease. Semin Liver Dis. 1993;13:170-182. (Pubitemid 23183172)
93. Wolff B, Burns AR, Middleton J, et al. Endothelial cell "memory" of inflammatory stimulation: Human venular endothelial cells store interleukin 8 in Weibel-Palade bodies. J Exp Med. 1998;188:1757-1762.
94. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370:218-220. (Pubitemid 24236777)
95. Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immuno-adhesin. Proc Natl Acad Sci USA. 1991;88:10535-10539. (Pubitemid 21915870)
96. Zhang H, Feng Q, Li HS, et al. Effects of Qushi Huayu Decoction on cathepsin B and tumor necrosis factor-alpha expression in rats with non-alcoholic steatohepatitis. Zhong Xi Yi Jie He Xue Bao. 2008;6:928-933.
97. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:619-638. (Pubitemid 39141146)
98. Lesmana CR, Lesmana LA, Akbar N, et al. Clinical picture, insulin resistance, and adipocytokines profiles of nonalcoholic steatohepatitis (NASH) patients in Indonesia. Acta Med Indones. 2009;41:6-10.
99. Schramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369-1371.
100. Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415-424. (Pubitemid 43268283)
101. Roilides E, Katsifa H, Tsaparidou S, et al. Interleukin 10 suppresses phagocytic and antihyphal activities of human neutrolphils. Cytokine. 2000;12:379-387. (Pubitemid 30449830)
102. Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol. 1996;15:181-187. (Pubitemid 26344648)
103. Poniachik J, Csendes A, Diaz JC, et al. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine. 2006;33:252-257.
104. De Groote D, Zangerle PF, Gevaert Y, et al. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine. 1992;4:239-248.
105. Mayringer I, Reindl M, Berger T. A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells. J Immunol Methods. 2000;235:33-40. (Pubitemid 30089781)